381 related articles for article (PubMed ID: 33359682)
1. Population-Based Frequency of Ophthalmic Adverse Events in Melanoma, Other Cancers, and After Immune Checkpoint Inhibitor Treatment.
Braun D; Getahun D; Chiu VY; Coleman AL; Holland GN; Yu F; Gordon LK; Sun MM
Am J Ophthalmol; 2021 Apr; 224():282-291. PubMed ID: 33359682
[TBL] [Abstract][Full Text] [Related]
2. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK
Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553
[TBL] [Abstract][Full Text] [Related]
3. Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database.
Anquetil C; Salem JE; Lebrun-Vignes B; Touhami S; Desbois AC; Maalouf G; Domont F; Allenbach Y; Cacoub P; Bodaghi B; Saadoun D
J Autoimmun; 2020 Jul; 111():102454. PubMed ID: 32303423
[TBL] [Abstract][Full Text] [Related]
4. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
[TBL] [Abstract][Full Text] [Related]
5. Risk of Immune-related Adverse Events in Melanoma Patients With Preexisting Autoimmune Disease Treated With Immune Checkpoint Inhibitors: A Population-based Study Using SEER-Medicare Data.
Tully KH; Cone EB; Cole AP; Sun M; Chen X; Marchese M; Roghmann F; Kilbridge KL; Trinh QD
Am J Clin Oncol; 2021 Aug; 44(8):413-418. PubMed ID: 34081033
[TBL] [Abstract][Full Text] [Related]
6. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of uveitis events in real-world patients receiving immune checkpoint inhibitors based on the FAERS database.
Fan Q; Chen H; Hu Y; Zhao B
Cutan Ocul Toxicol; 2023 Jun; 42(2):68-73. PubMed ID: 37130046
[TBL] [Abstract][Full Text] [Related]
8. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience.
Fortes BH; Liou H; Dalvin LA
Br J Ophthalmol; 2021 Sep; 105(9):1263-1271. PubMed ID: 32830124
[TBL] [Abstract][Full Text] [Related]
9. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
10. Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors.
Gan L; Chen H; Liu X; Zhang L
Front Immunol; 2023; 14():1130238. PubMed ID: 37033964
[TBL] [Abstract][Full Text] [Related]
11. The Risk Factors Associated with Immune Checkpoint Inhibitor-Related Pneumonitis.
Asada M; Mikami T; Niimura T; Zamami Y; Uesawa Y; Chuma M; Ishizawa K
Oncology; 2021; 99(4):256-259. PubMed ID: 33477139
[TBL] [Abstract][Full Text] [Related]
12. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
[TBL] [Abstract][Full Text] [Related]
13. Association between immune checkpoint inhibitor medication and uveitis: a population-based cohort study utilizing TriNetX database.
Kuo HT; Chen CY; Hsu AY; Wang YH; Lin CJ; Hsia NY; Tsai YY; Wei JC
Front Immunol; 2023; 14():1302293. PubMed ID: 38264654
[TBL] [Abstract][Full Text] [Related]
14. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
Nikolaou VA; Apalla Z; Carrera C; Fattore D; Sollena P; Riganti J; Segura S; Freites-Martinez A; Lallas K; Romano MC; Oikonomou C; Starace M; Dimopoulos MA; Kyrgidis A; Lazaridou E; Giavedoni P; Annunziata MC; Peris K; Echeverría M; Lopez-Tujillo E; Syrigos K; Papageorgiou C; Podlipnik S; Fabbrocini G; Torre AC; Kemanetzi C; Villa-Crespo L; Lallas A; Stratigos AJ; Sibaud V
Br J Dermatol; 2022 Dec; 187(6):962-969. PubMed ID: 35861701
[TBL] [Abstract][Full Text] [Related]
15. Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: A nationwide retrospective cohort study.
Kim YJ; Lee M; Kim EH; Lee S; Park S; Hong MH; Shin SJ; Jung I; Lee CK; Lee CS
Cancer Lett; 2024 Aug; 596():216998. PubMed ID: 38830470
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
17. Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study.
Salzmann M; Tosev G; Heck M; Schadendorf D; Maatouk I; Enk AH; Hartmann M; Hassel JC
Eur J Cancer; 2021 Jul; 152():41-48. PubMed ID: 34062486
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma.
Wong SK; Blum SM; Sun X; Da Silva IP; Zubiri L; Ye F; Bai K; Zhang K; Ugurel S; Zimmer L; Livingstone E; Schadendorf D; Serra-Bellver P; Muñoz-Couselo E; Ortiz C; Lostes J; Huertas RM; Arance A; Pickering L; Long GV; Carlino MS; Buchbinder EI; Vázquez-Cortés L; Jara-Casas D; Márquez-Rodas I; González-Espinoza IR; Balko JM; Menzies AM; Sullivan RJ; Johnson DB
Eur J Cancer; 2023 Mar; 181():188-197. PubMed ID: 36680880
[TBL] [Abstract][Full Text] [Related]
19. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
Purde MT; Niederer R; Wagner NB; Diem S; Berner F; Hasan Ali O; Hillmann D; Bergamin I; Joerger M; Risch M; Niederhauser C; Lenz TL; Früh M; Risch L; Semela D; Flatz L
J Cancer Res Clin Oncol; 2022 Mar; 148(3):647-656. PubMed ID: 34874490
[TBL] [Abstract][Full Text] [Related]
20. Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort study.
Wan G; Khattab S; Leung BW; Zhang S; Nguyen N; Tran M; Lin C; Chang C; Alexander N; Jairath R; Phillipps J; Tang K; Rajeh A; Zubiri L; Chen ST; Demehri S; Yu KH; Gusev A; Kwatra SG; LeBoeuf NR; Reynolds KL; Semenov YR
Br J Dermatol; 2024 Jun; 191(1):117-124. PubMed ID: 38366637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
